Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2
Drug: DUR-928
IV infusion
Drug: Placebo
IV infusion
Inclusion Criteria:
- Hospitalized with moderate, severe, or early critical COVID-19 illness diagnosed by
RT- PCR
- Acute liver injury (including acute on chronic liver disease) or acute kidney injury
or moderate COVID-19 pneumonia
Exclusion Criteria:
- Critical COVID-19 illness (MAP < 60 mm Hg, on mechanical ventilator for ≥ 5 days)
- On maintenance hemodialysis or peritoneal dialysis
- Child Pugh C cirrhosis
- Hepatorenal syndrome
- Ascites and/or hepatic encephalopathy
- History of end stage renal disease or CKD with eGFR < 15 mL/min/1.73m2
- Women who are pregnant or breast feeding
- Receipt of other concomitant experimental therapies
Site 03
Newark, New Jersey, United States
Robert Gordon, MD, Study Director
CTI Clinical Trial and Consulting Services